$9.93 $0.36 (3.8%)

04:30 PM EST on 02/21/20

DBV Technologies S.A. (NASDAQ:DBVT)

CAPS Rating: 5 out of 5

Current Price $9.93 Mkt Cap $961.7M
Open $9.44 P/E Ratio 0.00
Prev. Close $9.93 Div. (Yield) $0.00 (0.0%)
Daily Range $9.40 - $9.99 Volume 644,323
52-Wk Range $9.10 - $13.49 Avg. Daily Vol. 502,965

Caps

How do you think NASDAQ:DBVT will perform against the market?

Add Stock to CAPS Watchlist

All Players

15 Outperform
0 Underperform
 

All-Star Players

5 Outperform
0 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:DBVT Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:DBVT VS S&P 500 (SPY)

NASDAQ:DBVT Summary

Fools bullish on NASDAQ:DBVT are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about DBVT.

Recs

0
Member Avatar mdriver78 (70.13) Submitted: 2/19/2020 6:52:04 AM : Outperform Start Price: $9.44 NASDAQ:DBVT Score: +5.44

DBV specializes in epicutaneous immunotherapy (EPIT), a minimally invasive technology that eschews pills or needles. The company calls the technology Viaskin and it works through intact skin using a patch.

Our skin does much more than cover our bodies. It’s our largest organ! And it’s intelligent, working to respond to traumas, toxins and infectious diseases. It contains immune system cells that act to help the body present a proper response.

DBV’s Viaskin patch, once applied, hydrates the skin and makes an allergen soluble enough to get through the outer layers. Then once in, skin Langerhans cells take them up, preventing their entry to the blood stream. However, these antigen presenting cells do their work by migrating to lymph nodes, training the immune system.

Using this method DBV has devised how to train the immune system without the need to pass antigens into the bloodstream, reducing or eliminating the potential for an adverse immune system reaction.

This is really important. Food allergies can lead to anaphylactic shock, a deadly condition that has to be treated via an epinephrine injection. The FDA recently approved a competing oral product and epinephrine, allergic reactions and dropouts were much higher in patients using it.

DBV’s product, which recently reported long-term, three-year data for Viaskin Peanut in children with peanut allergies, showed no need for epinephrine use related to treatment. The worst side effects were mild to moderate skin reactions, making Viaskin a potentially superior option for allergy sufferers if the FDA approves.
And we won’t have to wait long for an FDA approval. DBV’s Viaskin Peanut has received both Breakthrough and Fast Track designations from the U.S. drug regulator. Moreover, DBV has filed with the FDA for children between 4 and 11 years of age with peanut allergies, with a decision expected on or before Aug. 5, 2020.

There’s a big market for peanut allergy treatment, with a year’s supply of Viaskin Peanut estimated to reach the market with a price in the neighborhood of $6,000. There are over 70 million kids in the U.S., and over a million of them have peanut allergies.
Capturing just half this market could generate revenues in excess of $1 billion for DBV, not counting the potential to expand into younger children or adults.

Moreover, the company is expanding its Viaskin platform to treat egg and milk allergies, too. Furthermore, the company has multiple programs in other areas of immunotherapy.

Right now, DBVT trades for $9.34 per share, with a market cap of $1.03 billion. Last month, the company raised gross proceeds of $153.7 million from a follow-on offering, ensuring enough cash runway to reach important regulatory catalysts like this summer’s FDA decision. DBV Technologies’ potential isn’t lost on savvy investors, either. Last quarter, legendary biotech investing firm Baker Bros. Advisors scooped up a whopping 9.1 million shares in addition to the 31 million already owned — bringing its total stake to almost 40% of the company.

Recs

0
Member Avatar OklaBoston (< 20) Submitted: 2/18/2020 9:30:30 AM : Outperform Start Price: $9.33 NASDAQ:DBVT Score: +7.75

Strength of All Star support and improving technicals.

Recs

0
Member Avatar Paco57 (30.14) Submitted: 1/9/2020 9:46:30 PM : Outperform Start Price: $13.48 NASDAQ:DBVT Score: -28.14

No Peanuts for you!

Leaderboard

Find the members with the highest scoring picks in DBVT.

Score Leader

sln

sln (65.78) Score: +72.76

The Score Leader is the player with the highest score across all their picks in DBVT.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
northcutt0 < 20 12/21/2018 Outperform 5Y $5.50 +80.55% +35.11% +45.44 0 Comment
OklaBoston < 20 2/19/2020 Outperform 3Y $9.33 +6.43% -1.32% +7.75 1 Comment
mdriver78 70.13 2/20/2020 Outperform 5Y $9.44 +5.20% -0.24% +5.44 1 Comment
Paward 35.36 2/19/2020 Outperform 3M $9.63 +3.12% -1.39% +4.51 0 Comment
drugtrader 92.37 2/19/2020 Outperform 5Y $9.76 +1.79% -1.56% +3.35 0 Comment
dagarcia1976 55.23 1/31/2020 Outperform 5Y $10.40 -4.52% +2.12% -6.64 0 Comment
portefeuille 98.57 4/29/2019 Outperform 5Y $10.34 -3.97% +13.58% -17.54 0 Comment
cobradon 96.34 1/16/2020 Outperform 5Y $12.82 -22.54% +1.13% -23.68 0 Comment
Paco57 30.14 1/10/2020 Outperform 5Y $13.48 -26.34% +1.81% -28.14 1 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. MarkBiotech < 20 3/7/2018 Outperform 5Y $22.21 -55.29% +22.66% -77.95 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for DBVT.